"id","uuid:ID","versionIdentifier","instanceType","rationale"
"StudyVersion_1","eaf58de3-1753-455c-b80b-bbfdb43f958f","2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
